T1	intervention 12 18	ginger
T2	condition 38 78	chemotherapy-induced nausea and vomiting
T3	eligibility 82 150	breast cancer patients receiving adriamycin-cyclophosphamide regimen
T4	eligibility 438 563	breast cancer patients receiving AC who experienced moderate to severe nausea or vomiting during the first chemotherapy cycle
T5	control 628 635	placebo
T6	duration 652 658	5Â days
T7	outcome-Measure 852 867	Nausea severity
T8	outcome-Measure 955 980	reduction in nausea score
T9	No-of-participants 982 993	Thirty-four
T10	No-of-participants 1108 1120	Thirty-three
T11	outcome 1224 1245	maximum nausea scores
T12	outcome 1343 1383	difference in mean maximum nausea scores
T13	outcome 1513 1612	vomiting incidence and severity, rescue medication use, chemotherapy compliance, and adverse events
